Chimerix Stock News

DURHAM, N.C., April 24, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients f

Chimerix, Inc. is a biotech company focused on developing novel treatments for high-grade glioma and other therapies. Their main clinical asset, doraviprone, has shown promising results in treating H3

DURHAM, N.C., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa

DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expe

Chimerix, Inc. (NASDAQ:CMRX ) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andr

Millionaire-maker penny stocks, as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily make you poo

When dealing with the best small-cap stocks to buy, investors effectively absorb higher risk for the possibility of substantive rewards. Even better, these rewards can come in quickly, enabling those

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of succes

Today, we put the spotlight on Chimerix, Inc. for the first time in 12 months. The company is advancing its primary oncology candidate in development, has a potentially large market, and sells for les

Typically, securities may be less appreciated by the market because they stink, which means several proposals for best undervalued growth stocks for June might not make the cut. At the same time, bett

The biotechnology firm Chimerix has a high probability of success in its ongoing clinical trial in the treatment of pediatric brain tumors, according to analysts at Baird.  The firm initiated coverag

Chimerix, Inc. (NASDAQ:CMRX ) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ET Company Participants Michelle LaSpaluto - Vice President of Strategic Planning and Investor Relations Mike Sherman

DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients f

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts